Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI, such as gefitinib) in lung Cancer continues to be a major problem. Recent studies have shown the promise of ferroptosis-inducing therapy in EGFR-TKI resistant Cancer, but have not been translated into clinical benefits. Here, we identified Carbonic Anhydrase IX (CA9) was upregulated in gefitinib-resistant lung Cancer. Then we measured the cell viability, intracellular Reactive Oxygen Species (ROS) levels, and labile iron levels after the treatment of Ferroptosis inducer erastin. We found that CA9 confers resistance to ferroptosis-inducing drugs. Mechanistically, CA9 is involved in the inhibition of transferrin endocytosis and the stabilization of ferritin, leading to resistance to Ferroptosis. Targeting CA9 promotes iron uptake and release, thus triggering gefitinib-resistant cell Ferroptosis. Notably, CA9 inhibitor enhances the ferroptosis-inducing effect of cisplatin on gefitinib-resistant cells, thus eliminating resistant cells in heterogeneous tumor tissues. Taken together, CA9-targeting therapy is a promising approach to improve the therapeutic effect of gefitinib-resistant lung Cancer by inducing Ferroptosis.